OA, the main MUFA in EVOO, has shown promise in NAFLD management by reducing hepatic steatosis, improving insulin sensitivity, and modulating hepatic glucose and lipid metabolism through mechanisms that inhibit ER and oxidative stress and inflammation [182]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.